BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23134470)

  • 1. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
    Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between serum hepatitis B virus DNA load and hepatocellular carcinoma in Qidong, China: a cohort follow-up study of 14 years].
    Sun Y; Chen TY; Lu PX; Wang JB; Wu Y; Zhang QN; Qian GS; Tu H
    Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(27):1874-7. PubMed ID: 23134955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
    Momosaki S; Nakashima Y; Kojiro M; Tabor E
    J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Difference of HBV DNA levels and HBV genotypes between the patients with primary hepatocellular carcinoma and liver cirrhosis with hepatitis B].
    Wang JH; Zhou M; Li Y; Deng J; Wu XX; Cheng W; Gu XB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Aug; 25(4):245-7. PubMed ID: 22097598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma.
    Wang M; Qiu N; Lu S; Xiu D; Yu J; Wang XT; Lu F; Li T; Liu X; Zhuang H
    J Med Virol; 2013 Feb; 85(2):219-27. PubMed ID: 23168998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
    Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
    J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
    Chen JD; Yang HI; Iloeje UH; You SL; Lu SN; Wang LY; Su J; Sun CA; Liaw YF; Chen CJ;
    Gastroenterology; 2010 May; 138(5):1747-54. PubMed ID: 20114048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg.
    Lee JH; Kim SJ; Ahn SH; Lee J; Park Y; Kim HS
    J Clin Pathol; 2010 Nov; 63(11):1027-31. PubMed ID: 20870658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
    Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
    Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.
    Tsai FC; Liu CJ; Chen CL; Chen PJ; Lai MY; Kao JH; Chen DS
    J Viral Hepat; 2007 Mar; 14(3):153-60. PubMed ID: 17305880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
    Huo TI; Wu JC; Lee PC; Chau GY; Lui WY; Tsay SH; Ting LT; Chang FY; Lee SD
    Hepatology; 1998 Jul; 28(1):231-6. PubMed ID: 9657117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
    Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ;
    Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.